News & Events

Clinical Studies

Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA

Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor

6 December 2021

Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes

27 October 2021

The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH

20 October 2021

Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH

8 September 2021

Inventiva to Present Corporate Overview at the Cowen and Company 39th Annual Health Care Conference

The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI

Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH

21 February 2019

Inventiva Announces Results From Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis

18 February 2019

New results on lanifibranor to be presented at the International Liver Congress™ 2019

4 February 2019

Inventiva Announces Poster Presentation on Its YAP/TEAD Inhibitor Program at the EORTC-NCI-AACR Symposium in Dublin

7 November 2018

Inventiva Announces Last Visit by Last Patient in its Phase IIb SSc Trial and Second Positive DSMB Review in its Phase IIb NASH Trial with Lanifibranor

15 October 2018

Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment

24 September 2018

Inventiva advances in the development of lanifibranor with the achievement of three key milestones

Inventiva’s lanifibranor found to have good safety profile following first assessment of carcinogenicity studies’ results

Inventiva to Present the Latest Findings in its RORγ program at the 256th National Meeting of the American Chemical Society

Inventiva Announces Positive DSMB Reviews in both NASH and Systemic Sclerosis Phase IIb Trials with Lanifibranor

FDA Approval of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease

Inventiva Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes

Lanifibranor carcinogenicity studies: Progressing as planned and interim results in rats indicate no compound related urinary bladder tumors

Inventiva announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients

26 February 2018

Inventiva Announces Positive DSMB Review in Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor

Inventiva Announces Enrollment of First Patient into Its Odiparcil Phase IIa Trial (iMProveS) for MPS VI

Inventiva’s Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor Completes Enrollment

17 October 2017

Inventiva and AbbVie Extend Agreement to Discover New Potent Orally-Available Small Molecule RORγ Inverse Agonist Drug Candidates

4 September 2017

Inventiva’s Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the European Medicines Agency

Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the FDA

Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference

Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models

Inventiva Announces Positive Results of 12 Month Primate Toxicity Study with IVA337

Inventiva Announces Presentation of Preclinical Results on IVA337 in NASH at the International Liver Congress™ 2017 (EASL)

Inventiva Hits Clinical Milestone with Enrollment of 100th Patient in IVA337 Phase 2b FASST Trial in Systemic Sclerosis (SSc)

Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)

Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis

Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress

25 February 2016

IVA337 delivers significant therapeutic advances in fibrosis, a major public health challenge

28 January 2016

European Eurostars funding received for epigenetics program NSD2

3 December 2015

SensiQ Technologies and Inventiva set up a European Center of Excellence in surface plasmon resonance (SPR) technologies

9 February 2015

Inventiva receives another positive opinion on orphan drug designation in the European Union for IVA337 – for Idiopathic Pulmonary Fibrosis

2 December 2014

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
ak_bmsc	2 hours	This cookie is used by Akamai to optimize site security by distinguishing between humans and bots
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
JSESSIONID	session	The JSESSIONID cookie is used by New Relic to store a session identifier so that New Relic can monitor session counts for an application.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Cookie	Duration	Description
pll_language	1 year	The pll _language cookie is used by Polylang to remember the language selected by the user when returning to the website, and also to get the language information when not available in another way.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_173436417_1	1 Jour/s	Ces cookies sont utilisés pour collecter des informations sur la façon dont les visiteurs utilisent notre site Web. Ceci est unique au propriétaire du site Web
_gat_gtag_UA_55628332_1	1 minute	Set by Google to distinguish users.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Cookie	Duration	Description
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Cookie	Duration	Description
43410	session	No description available.
43411	session	No description
bm_mi	session	No description available.
DrupalVisitorMobile	session	No description available.
GZIP	5 years	No description available.

Inventiva receives another positive opinion on orphan drug designation in the European Union for IVA337 – for Idiopathic Pulmonary Fibrosis